Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
A Supportive Membership Offer While You Plan Your Next Step
Being made redundant, or finding yourself between roles for any reason, can be an unsettling time. It can also be an important moment to reconnect with your professional community, explore new opportunities, and invest in your next step.
*Guest blog by Gavin Allsop, Commercial Director, Lab Thread. If you would like to submit a guest blog please email [email protected].
Established in 2005, the DLRC Group has developed a deserved reputation for being a leading consultancy, with a wealth of regulatory and scientific knowledge and considerable experience in both leadership and management. The company has recently expanded to include affiliates based in Germany and the US.
The John Innes Centre (JIC) seeks a creative junior or established researcher to set up and lead an internationally excellent, independent research programme in fundamental plant biology relevant to legumes or other rotation crops. The postholder is encouraged to address biological questions with clear relevance to UK agriculture.
The RESI Conference will be held on January 11-12 at the San Francisco Marriott Marquis, featuring two days in-person event followed by three days (January 13, 18 & 19) of online partnership activities. Previous RESI JPM conferences have drawn over a thousand attendees, including more than 600 early-stage life science investors, innovators, and industry experts. This RESI is held concurrently with JP Morgan Healthcare Week.
The apparent tectonic shift in the global bio-innovation landscape has markedly accelerated, and 2025-26 is providing One Nucleus members with exciting opportunities and huge challenges like never before. Adapting to maintain the key role of convener, supporter, ally and compass for members navigating these changes has led One Nucleus to invest in developing a new toolbox to help our members.
Tagomics is a Cambridge-based biotechnology company developing a next-generation multi-omic platform to transform how disease and drug safety are understood, measured and monitored.
Our proprietary technology extracts genetic, epigenetic and fragmentomic information from circulating cell-free DNA. Combined with advanced bioinformatics and machine learning, it enables deep biological insight across applications including drug safety, organ health monitoring and cancer detection.
🔹 Project Manager
🔹 Senior/Principal Assay Development Scientist (Genetic Code Expansion)
🔹 Research Associate (tRNA)
🔹 Lead Scientist (Novel Biomolecule Process Development)